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Early clinical trials designed to treat Parkinson’s disease by transplantation of fetal tissue containing dopa-
mine neuron precursors yielded promising results, but the approach retains several limitations. Multiple
recent papers describe longer-term outcomes in these patients, and two additional studies offer novel
approaches that may lead to autologous sources of transplantable dopamine neurons.The first clinical trials that used dopamine
neuron replacement therapy for Parkin-
son’s disease (PD) were carried out in
Sweden almost 20 years ago by trans-
planting aborted fetal brain tissue into
the brains of PD patients (Lindvall et al.,
1990). Remarkably, the transferred tissue
harbored immature dopamine neurons
that integrated into the striatum, produced
dopamine, and in somecaseswereable to
replace drug treatments. However, initial
optimism faded when subsequent dou-
ble-blind trials revealed less substantial
effects and a few patients developed
dyskinesias, or abnormal movements
(Olanow et al., 2003; Freed et al., 2001).
Today, only a few clinical trials are still
ongoing as the field holds its breath and
waits for the answers to many technical
questions. Is there an alternative to using
fetal tissue? Will the transplanted cells
always be susceptible to rejection? Will
grafts succumb to the disease process
that killed the endogenous dopamine
neurons? Can troublesome dyskinesias
be avoided? Can dopamine neuron trans-
plants really provide a cure in a complex
disease like PD? Five new papers address
some of these issues and are the focus of
this article.
The use of fetal tissue as a cell source
for clinical transplantation is not very412 Cell Stem Cell 2, May 2008 ª2008 Elsevpractical, as developing dopamine neu-
rons are rare and only available from
exactly 8-week-old embryos. Cells from
younger donors will not be patterned cor-
rectly, and older cells will not survive. In
the early 1990s, researchers began to
ask whether stem cells might offer an al-
ternative. It quickly became evident that,
while human cells isolated from the fetal
tissue used in clinical transplantation
studies could be expanded in culture
and survive transplantation into rodent
models of PD, they failed to generate
significant numbers of dopamine neurons
when compared to primary tissues
(Svendsen et al., 1996). In a seminal pub-
lication by McKay and colleagues, this
problem was overcome by using mouse
embryonic stem cells (ESCs) as a starting
source. Unlike their fetal counterparts,
ESCs produce large numbers of func-
tional dopamine neurons that, when
transplanted, can restore function in
rodent models of PD (Kim et al., 2002).
This exciting work on ESCs has now
been extended in two important ways.
First, Studer and colleagues derived
murine embryos via nuclear transfer using
donor fibroblasts isolated from mice with
experimentally induced PD (Tabar et al.,
2008). The resulting blastocysts were
used to generate ESCs, whichwere differ-ier Inc.entiated into dopamine neurons and
transplanted back into the original fibro-
blast donor mice. Importantly, this study
observed improved graft survival and
functional recovery when autologous
ntESCs were transplanted, suggesting
that using exactly matched cells may
reduce immune rejection. In an indepen-
dent, but related, study, Jaenisch and
colleagues bypassed the need for nuclear
transfer with induced pluripotent stem
(iPS) cells derived by the enforced expres-
sion of four transcription factors in adult
fibroblasts (Yamanaka, 2007). Existing
murine iPS cell lines were differentiated
into neural lineages and then dopamine
neurons by using established techniques
(Wernig et al., 2008). The resulting cells
were subsequently transplanted into
a rat model of PD, where they elicited
functional improvement. In both of these
proof-of-principle studies, the authors
conclude that dopamine neurons pro-
duced from either clonedmouse embryos
or reprogrammed skin cells are able to
functionally integrate into the brain and
release dopamine—perhaps the best ob-
tainable evidence that neurons derived
using these methods can mature appro-
priately.
Of course, translating these exciting
mouse studies to human PD patients is
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nity to use autologous cells to generate
dopamine neurons is appealing, as it
would yield transplants with very low re-
jection levels. Indeed, while human ESC
lines have not yet been established by
using nuclear transfer techniques, recent
observations that iPS cells can be gener-
ated from human fibroblasts is encourag-
ing (reviewed in Jaenisch and Young,
2008). However, the logistical challenge
of having to produce individual, patient-
specific cell lines is daunting, particularly
in the case of nuclear transfer, given the
number of egg donors that would be
required. Furthermore, to date, iPS cell
derivation requires the insertion of multi-
ple genes and, when combined with the
poorly understood genomic alterations
associated with reprogramming, raises
important safety issues. Finally, while
many PD patients do not bear known mu-
tations for PD, they may still exhibit novel,
unidentified susceptibility gene profiles.
Thus, an autologous transplant might be
at risk of an accelerated course of patho-
logical changes relative to cells from a
healthy donor.
Beyond the question of the source of
dopamine neurons for transplantation,
two additional reports of patients receiv-
ing fetal tissue grafts address the
long-term potential of this therapy para-
digm. The studies reveal that some of
the surviving dopamine neurons exhibit
pathological changes associated with
PD (Li et al., 2008; Kordower et al.,
2008). This raises the fascinating possibil-
ity that the aging, diseased environment
transmits a toxic signal to the grafted
neurons, in which case transplanted cells
from any source would be equally threat-
ened. However, while these results dem-
onstrate that grafted cells can exhibit PD
pathology, only a few neurons appear to
be affected. In addition, a third study of
other grafted PD patients did not observe
any pathology in the transplanted dopa-
mine neurons (Mendez et al., 2008). Over-
all, while the recent human studies offer
insight into the potential spread of PD
pathology, the jury is still out on the rele-vance of a few aberrant neurons to this
therapeutic approach.
Together, it seems that these five stud-
ies leave us with an added appreciation
for the remaining hurdles that face dopa-
mine neuron replacement therapies for
PD. Stem cells certainly offer an ideal
source of dopamine neurons, and these
latest studies imply that autologous cells
may one day be available for transplant
therapies, provided the diseased host
environment does not prevent their func-
tion. But perhaps the taller hurdles lie
ahead. Themechanismsunderlyingdyski-
nesias that appear in some transplant
patients must be elucidated to increase
safety. Stem cells may be used to tackle
this problemaswell, ifmore defineddopa-
mine populations can be produced, or
engineered by using inducible promoters
to control dopamine release. In this way,
the patient could take a drug to activate
dopamine production for better control
of neuronal activity. The next hurdle is
higher still. Most current transplant strate-
gies for PD deposit the cells ectopically in
the striatum, a forebrain structure. While
convenient for dopamine neurons to con-
nect to their target, the location of the en-
dogenous, damaged dopamine neurons
is buried deep in the midbrain, many cen-
timeters away. In order to restore the orig-
inal circuit, dopamine neuronsmustbeen-
grafted back into the midbrain and then
undergo long-distance axon regeneration
to targets in the striatum. If possible, this
approach has the potential to restore
physiologically relevant input to the new
dopamine neurons and perhaps provide
the normal fine control over dopamine
release that characterizes this system.
However, extensive long-distance axonal
outgrowth into the adult brain has been
difficult to achieve in other studies.
The final hurdle facing dopamine neu-
ron replacement strategies is that PD
pathology is not restricted to the loss of
dopamine neurons. Many other systems
degenerate in PD patients and may need
to be addressed in addition to re-estab-
lishing dopamine signals in the brain. But
dopamine replacement may be only partCell Steof the story. Stem cells can also produce
astrocytes, which are able to modulate
synaptic transmission, toxic glutamate
levels, and the blood-brain barrier func-
tion. They can also be genetically modi-
fied to release powerful drugs within spe-
cific brain regions. So, while cures based
on dopamine neuron transplantation may
not be around the corner, stem cells offer
many new potential avenues of therapy
for PD patients that may compliment
current treatments.
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